{
}
US tech stocks faced pressure as Alphabet's shares dropped over 8% following disappointing cloud earnings, while AMD fell nearly 10% amid concerns over its AI processor competitiveness against Nvidia. In contrast, Broadcom rose 4% due to its ties with Alphabet. The dollar weakened amid geopolitical uncertainties and mixed economic data, while gold prices reached a record high.
UBS Global Research has downgraded Sandoz to "neutral," citing limited upside in biosimilar growth and a forecasted 3% lower growth rate than consensus estimates. Despite a strong share price performance, analysts anticipate potential downside to 2025 projections, with Sandoz's biosimilar sales expected to fall 2% below consensus. The firm has raised Sandoz's target price to CHF 44 due to foreign exchange adjustments, while litigation risks and slower growth in generics pose challenges ahead.
The global cancer immunotherapy market is projected to reach $135.2 billion in 2024, growing at a CAGR of 9.8% to $236.9 billion by 2030, driven by rising cancer prevalence and demand for effective treatments. North America leads the market, while Asia-Pacific is the fastest-growing region. Monoclonal antibodies dominate the product segment, with lung cancer applications holding the largest market share, and breast cancer expected to grow the fastest.
The Congestive Heart Failure market is poised for significant growth, driven by an increase in prevalence and the introduction of innovative therapies like finerenone, tirzepatide, and semaglutide. Key players such as Novartis, Eli Lilly, and Bayer are advancing their drug candidates through clinical development, while off-label therapies and generics continue to dominate the current market landscape. The FDA's recent approvals and label expansions are expected to further enhance treatment options and accessibility for patients.
The semaglutides market is projected to grow from $20.54 billion in 2023 to $36.87 billion by 2028, driven by rising diabetes prevalence and increased demand for effective treatments. Key players are innovating with GLP-1 receptor analogues and oral formulations to enhance patient adherence and reduce side effects. North America leads the market, while Asia-Pacific is expected to be the fastest-growing region.
UBS analyst Trung Huynh reports that Novo Nordisk's CagriSema Phase 3 obesity data fell short of expectations, achieving a 20.4% average weight loss compared to the anticipated 25%. This outcome is seen as favorable for Eli Lilly and Amgen, reinforcing tirzepatide's leading position and suggesting CagriSema's efficacy aligns more closely with MariTide, which may have gastrointestinal side effects.
UBS analyst Trung Huynh reports that Novo Nordisk's CagriSema Phase 3 obesity data fell short of expectations, achieving a 20.4% average weight loss compared to the anticipated 25%. This outcome is seen as favorable for Eli Lilly and Amgen, reinforcing tirzepatide's leading position in the market. The analysis suggests that CagriSema's efficacy aligns more closely with MariTide, which may present gastrointestinal issues and a less appealing monthly titration regimen.
Novartis is closing MorphoSys sites in Munich and Boston, resulting in approximately 330 layoffs, as part of its integration strategy following the €2.7 billion acquisition earlier this year. The decision aligns with a focus on prioritizing R&D programs, particularly the delayed approval pathway for the oncology candidate pelabresib. This trend of post-acquisition job cuts has been observed across several major pharma companies in recent years.
BioAge Labs has entered a multi-year partnership with Novartis to tackle age-related diseases, potentially worth up to $550 million. The collaboration will leverage BioAge's human longevity datasets and Novartis's expertise in exercise biology to discover new therapeutic targets and explore the biological mechanisms of aging. This agreement follows BioAge's recent IPO and the discontinuation of a phase 2 obesity trial due to safety concerns.
Regeneron's Eylea HD has demonstrated noninferior visual acuity gains compared to the original Eylea in patients with macular edema following retinal vein occlusion, paving the way for a 2025 FDA filing. The drug, which generated $392 million in U.S. sales in Q3, faces competition from Amgen's biosimilar and Roche's Vabysmo, but its potential approval in RVO could boost sales further.
Amgen Inc.
Companies
| Symbol | AMGN |
| Name | Amgen Inc. |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Pharmaceuticals |
| Market | NASDAQ Global Select |
| Country | United States |
| State | CA |
| City | Thousand Oaks |
| Zipcode | 91320-1799 |
| Website | http://www.amgen.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
us tech stocks face pressure as earnings reports and economic data emerge
British Pound Sterling
Swiss Franc
Japanese Yen
Euro
United States Dollar
Valiant Holding AG
AMD/BRX
ABB Ltd
Kudelski SA
Apple Inc.
RICHEMONT, Intellectual Property Services
NATURENERGIE N
SGS SA
Sika AG
Amgen Inc.
FMC Corp
dormakaba Holding AG
NVIDIA Corporation
The Walt Disney Co
Alphabet Inc.
Broadcom Inc.
Amazon.com, Inc.
Nestlé S.A.
Partners Group Holding AG
Swiss Life Holding AG
JPN
IND
KOR
AUS
HKG
CHN
CHE
USA
Donald Trump
Show more
05:52 06.02.2025
ubs downgrades sandoz to neutral amid biosimilar growth concerns
13:16 03.02.2025
global cancer immunotherapy market projected to reach 236.9 billion by 2030
United States Dollar
GSK plc
Bristol-Myers Squibb Company
Bayer AG
Eli Lilly and Company
Pfizer Inc.
Merck & Co., Inc.
Novartis AG
Immunocore Holdings plc
AstraZeneca PLC
Amgen Inc.
F. Hoffmann-La Roche Ltd.
IND
FRA
ARG
CAN
ESP
USA
BRA
CHN
MEX
DEU
ITA
JPN
GBR
KOR
Show more
10:06 10.01.2025
congestive heart failure market poised for significant growth by 2034
United States Dollar
Mesoblast Ltd
Eli Lilly and Co
Boehringer Ingelheim KG
Bayer AG
Merck & Co., Inc.
Bristol-Myers Squibb Co
Intra-Cellular Therapies, Inc.
BioCardia, Inc.
Novo Nordisk A/S
scPharmaceuticals Inc.
Lexicon Pharmaceuticals, Inc.
Cytokinetics, Incorporated
Novartis AG
Tenax Therapeutics, Inc.
AstraZeneca PLC
Amgen Inc.
Otsuka Pharmaceutical Co. Ltd.
FRA
DEU
ITA
JPN
GBR
USA
Show more
15:50 07.01.2025
semaglutides market projected to reach 36.87 billion by 2028
United States Dollar
Adocia SA
Sanofi SA
Eli Lilly and Company
Roche Holding AG
Pfizer Inc.
Merck & Co., Inc.
Dr. Reddy's Laboratories Limited
Boehringer Ingelheim International GmbH
Glaxosmithkline plc
Takeda Pharmaceutical Company Limited
AbbVie Inc.
Novartis International AG
Bristol-Myers Squibb Company
Novo Nordisk A/S
Cipla Limited
Biocon Limited
Teva Pharmaceutical Industries Ltd
AstraZeneca PLC
Amgen Inc.
ITA
IND
FRA
IDN
CAN
ESP
BRA
USA
RUS
CHN
DEU
AUS
JPN
GBR
KOR
Show more
10:12 06.01.2025
Eli Lilly and Amgen benefit from Novo Nordisk's disappointing obesity data
13:30 21.12.2024
Novo obesity data boosts outlook for Eli Lilly and Amgen stocks
13:30 21.12.2024
Novartis to close MorphoSys sites and lay off 330 employees
Euro
Sanofi
GSK plc
Gilead Sciences, Inc.
Incyte Corp
Novartis AG
Immunomedics Inc.
Horizon Therapeutics Public Lim
Bellus Health Inc.
Merck & Co., Inc.
Bristol-Myers Squibb Co
Amgen Inc.
MorphoSys AG
USA
DEU
CHE
Vas Narasimhan
Show more
15:47 19.12.2024
novartis and bioage partner to tackle age-related diseases in major deal
United States Dollar
Novartis AG
Amgen Inc.
BioAge Labs, Inc.
Eli Lilly and Company
USA
CHE
Lai Peng Leong
Michaela Kneissel
Kristen Fortney
Show more
16:44 18.12.2024
Regeneron advances Eylea HD for retinal vein occlusion amid rising competition
United States Dollar
Bayer AG
Regeneron Pharmaceuticals, Inc.
Hoffmann-La Roche AG
Amgen Inc.
USA
George Yancopoulos
Show more
14:20 18.12.2024
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Industry Mergers & Acquisitions
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Workplace Trends
Retail and Consumer Goods
CEO Changes
Market Analysis and Predictions
Global Trade Developments
Central Bank Actions
Startups & Entrepreneurship
Government Policies
Government Economic Policies
Financial Scams and Security
Domestic Politics
Corporate Social Responsibility
Supply Chain Management
Countries:
Companies:
JPMorgan Chase & Co.
Tesla, Inc.
Barclays PLC
UniCredit S.p.A.
Deutsche Bank Money Market PP
Banco BPM S.p.A.
Credit Suisse Lux Digital Healt
Bank of America Corporation
UBS Group AG
BNP Paribas SA
Apple Inc.
The Goldman Sachs Group, Inc.
Commerzbank AG
CREDIT AGRICOLE
Lloyds Banking Group plc
Wells Fargo & Company
Banco Santander, S.A.
Credit Suisse Strategic Income I
Amazon.com, Inc.
SpaceXCoin USD
Currencies:
United States Dollar
Euro
British Pound Sterling
Swiss Franc
Chinese Yuan
Indian Rupee
Japanese Yen
South Korean Won
Danish Krone
Hong Kong Dollar
Australian Dollar
Offshore Chinese Yuan
Singapore Dollar
Canadian Dollar
Mexican Peso
Norwegian Krone
Indonesian Rupiah
Russian Ruble
Chilean Peso
United Arab Emirates Dirham
People: